Investigación y Desarrollo

Research and Development

The heart of VaxThera is research and development. Through scientific innovation and excellence in our biotechnological processes, we aim to save lives and improve the quality of life for people.

As a Colombian company, VaxThera is well aware of what our territory needs, and based on that knowledge, we will deliver the solutions that our country needs and deserves in terms of technology.

In our research and development pipeline, we are focused on tropical emerging diseases that are prevalent in some areas of Latin America:

Research Headquarters

State-of-the-art technologie

Thanks to the technology and quality of our laboratory facilities, at VaxThera, we will have the capability to conduct rigorous research studies, design, produce, and validate vaccine candidates, optimize production processes, and generate high-quality vaccines and biologics for use in preclinical studies.

Ongoing Projects

Univax: we have developed a universal vaccine against SARS-CoV-2 on the viral vector platform. The vaccine has been shown, in preclinical stages, to be safe, immunogenic and effective against several variants of the virus. This vaccine is in the evaluation stage to initiate clinical trials.
Colombian Ministry of Science, Technology, and Innovation: Vaccines against Zika, chikungunya, and yellow fever are being developed through a partnership with the University of Wisconsin and the Universidad Nacional de Colombia, funded by the Colombian Ministry of Science, Technology, and Innovation. Our goal is to develop and evaluate the vaccines up to the preclinical level, using two technological platforms: viral vector and mRNA.
United States Department of Agriculture (USDA) – SARS-CoV-2: In partnership with the University of Wisconsin – Madison, we are currently evaluating our universal COVID-19 vaccine (UniVax) to limit virus transmission in multiple animal species and reduce the risk of transmission to humans. Additionally, we are working on developing a formulation that allows the vaccine to be administered orally or intranasally while maintaining its protective properties.

Research team

At VaxThera, we are committed to transparency and quality in our research. This is why, as a company and research team, we are registered on SCIENTI, the platform of the Colombian Ministry of Science, Technology, and Innovation, aiming to establish connections with other companies in the sector to enhance the ecosystem.